A Phase II Study of Dasatinib in Patients With Imatinib Resistant or Intolerant Chronic Myeloid Leukemia
Interventional
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
rate of Major Molecular Responses (MMR) in chronic phase chronic myeloid leukemia subjects
at 12 months
No
Hisashi Sakamaki, MD.PhD
Principal Investigator
Tokyo Metropolitan Cancer and Infectious diseases Center Komagome Hospital
Japan: Institutional Review Board
KCSG-01
NCT00866736
March 2009
October 2013
Name | Location |
---|